EU First To Approve Novartis’s Cholesterol Drug Leqvio

Twice Yearly Dosing Is Key Selling Point

 
• By Andrew McConaghie
  
Novartis_Building
Novartis is banking on Leqvio becoming a cardiovascular blockbuster.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Cardiovascular

More from Therapeutic Category